Multicenter randomized open study of the effectiveness of changed life quality and therapy with angiotensin-converting enzyme inhibitors (quinapril) in obese patients with arterial hypertension (ECO)

The wide spread of obesity in the populate in, and the increased risk of cardiovascular events, and type 2 diabetes mellitus (DM) in this group of patients served as the basis of the ECO study. Therapeutic approaches to treating arterial hypertension (AH) in patients with metabolic syndrome and type 2 DM have their peculiarities. Properly chosen antihypertensive therapy may also contribute to not only its good antihypertensive effect, but to better carbohydrate and lipid metabolic parameters. A decrease in weight may lead to the lowering of blood pressure and to the normalization of metabolic disorders. Obesity is pathogenetically related to AH, and it is apparent that the use of the newest and effective antihypertensive drugs will not be rather effective without concurrent treatment of obesity. But the main task of the study was to provide an opportunity to physician to be, from his/her own experience, convinced of the effectiveness of nondrug measures and their combination with antihypertensive therapy with the drug of choice (the angiotensin-converting enzyme inhibitor quinapril) in treating this group of patients. With this study, the authors would like to pay the attention of physicians and patients to the problem of obesity and All and to the hazard presented by these diseases.

obesity, arterial hypertension, its treatment, type 2 diabetes mellitus, angiotensin-converting enzyme inhibitors, quinapril, clinical study, nondrug measures, well-balanced diet

1. Seidell J.C., Flegall K.M., Accessing Obesity: < Classification And Epidemiology. Br Med Bull 1997:53: 238 - 52.

2. Mikhait N., Golub M., Tuck M. Obesity and hypertension. Prog Cardiovasc Dis 1999: 42 (1): 39 — 58.

3. Kannel W.B. McGee D.L.Diabetes and cardiovascular risk factors: tbe Framingbam Study. Circulation 1979; 59: 8-13.

4. Stamler J., Epidemic obesity in the United States. Arch Intern Med 1998; 150: 1040 - 4.

5. Чазова Е.И. Мычка B.Б., Стукалова О.В., Синицын В.Е. Роль ингибиторов АИФ в лечении сахарного диабета типа 2; фокус на аккупро. Артериальная гипертензия 2002: 8 (6): 209 — 11.